Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-527 in Healthy and HCV-Infected Subjects
NCT03219957Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing AT-527 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 35. Started Jul 2017; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03219957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219957.